The December issue of the Journal of Cardiac Failure (JCF), now available, offers a robust lineup of original research, ...
HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo ...
Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be self-administered by patients every four or eight weeks. The first-in-class drug targets ...
Recently Dentistry Live saw Drs Jin Vaghela and Kish Patel deliver a live webinar on revolutionising early caries treatment.
Orca Bio presents positive new data from its pipeline of allogeneic T-cell immunotherapies at the 67th ASH Annual Meeting.
Pharvaris ( (PHVS) ) has provided an announcement.
More than 40 per cent of people living with HIV in the Ashanti Region are currently not on treatment, posing a significant ...
HIV treatment has entered a revolutionary new era, one where a single yearly injection can keep the virus undetectable, and ...
On World AIDS Day, City Health reports over 90,000 individuals receiving ART, highlighting efforts to improve HIV services ...
In the last year, over 40 million people in the world were living with human immunodeficiency virus (HIV). In 2024, over a ...
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback